Cytokine PharmaSciences Inc. Acquired by Ferring Pharmaceuticals

Saint-Prex, Switzerland – October 20, 2011 – Cytokine PharmaSciences Inc.—a specialty biopharmaceutical company focused on women’s health—and its UK pharmaceutical manufacturing subsidiary Controlled Therapeutics (Scotland) Ltd., announced their sale to Ferring Pharmaceuticals. Based in Switzerland, Ferring is well-established in the field of reproductive health and believes that the acquisition of Cytokine will strengthen its position over the next few years.

“This acquisition advances our vision to become the global scientific and commercial leader in reproductive health, and perfectly complements our already strong portfolio of obstetrics products including TRACTOCILE® (atosiban) and PABAL® (carbetocin). In addition, the acquisition includes the manufacturing assets for dinoprostone marketed by Forest Laboratories, Inc. as CERVIDIL® in the US and Canada, and by Ferring as PROPESS® elsewhere. This acquisition gives us the opportunity to integrate the product portfolio into Ferring on a global basis and to extend our presence in this important field,” commented Michel Pettigrew, President of the Executive Board and COO at Ferring.

Cytokine also has developed a strong pipeline of women’s healthcare products, including the misoprostol vaginal insert which is to be marketed in the US and Canada as MISODEL®, and in Europe and the rest of the world as MISOPESS®. The new treatment is anticipated to be filed for FDA approval in 2012. It is estimated that there are 130 million babies born globally each year and, depending on the country, that labor induction rates range from 15% to 30% of all births. Treatments for cervical ripening are set to play an increasingly prominent role in the delivery process.

Fairmount Partners advised Cytokine, providing a fairness opinion to its Board of Directors. David Reed, Director, commented, “We have worked with Cytokine over the past five years helping the Company in a variety of strategic areas, and assisting the company in raising funds for expansion, and we are especially pleased to have been selected to work with them on this important transaction.”

About Cytokine PharmaSciences

Cytokine PharmaSciences, Inc. is a specialty pharmaceutical company engaged in developing anti-inflammatory and autoimmune therapeutics. The Company is headquartered in King of Prussia (near Philadelphia), Pennsylvania. A wholly owned subsidiary, Controlled Therapeutics (Scotland) Limited (CTS), is located in East Kilbride (near Glasgow). CTS develops and manufactures controlled-release drug delivery products and has a strong focus in the area of women’s health. For more information, please visit the company’s websites at www.cytokinepharmasciences.com and www.ctscotland.com.

About Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in more than 50 countries and markets its products in more than 70 countries. To learn more about Ferring or its products please visit www.ferring.com.

Principals of Fairmount Partners acted as advisors to Cytokine in this transaction.

Contact

Neal McCarthy

Managing Director, Fairmount Partners

neal.mccarthy@fairmountpartners.com